We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

This study is currently recruiting participants.
Verified February 2017 by Beckman Laser Institute and Medical Center, University of California, Irvine
Sponsor:
ClinicalTrials.gov Identifier:
NCT00581503
First Posted: December 27, 2007
Last Update Posted: February 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Beckman Laser Institute University of California Irvine
Information provided by (Responsible Party):
Beckman Laser Institute and Medical Center, University of California, Irvine
  Purpose
This study has been designed to utilize already obtained biopsy specimens for investigation of the utility of a new, non-invasive optical diagnostic technique. The study will allow a careful correlation between the Optical coherence tomography findings and conventional histology.

Condition Intervention
Lung Cancer Pleural Cancer Prostate Cancer Device: diagnostic

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Beckman Laser Institute and Medical Center, University of California, Irvine:

Primary Outcome Measures:
  • Pathology results. [ Time Frame: 30 minutes ]

Estimated Enrollment: 40
Study Start Date: March 2007
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
diagnostic
oct imaging
Device: diagnostic
oct imaging

Detailed Description:
Optical coherence tomography is a non-invasive diagnostic technique that can provide information about tissue abnormalities, change in structure of an organ. This technique uses a near-infrared diode to emit light that can produce images of the specimen under investigation without causing damage or alterations.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study Population will be identified at UCIMC, who is scheduled for prostatectomy, endobronchial, transbronchial, and pleural biopsy will be recurited to participate in the study.
Criteria

Inclusion Criteria:

  • Adult 18 years and older
  • Having procedure of endobronchial, transbronchial, and / or pleural biopsy

Exclusion Criteria:

  • Currently participating in any other investigational drug or device evaluation.
  • Currently taking drugs that are sensitive to light.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00581503


Contacts
Contact: Matthew Brenner, M.D (714)456-5150 mbrenner@uci.edu
Contact: Sari Mahon, PhD (949)824-3924 mahonsb@uci.edu

Locations
United States, California
Pulmonary and Critical Care Medicine, UCI Medical Center Recruiting
Orange, California, United States, 92868
Contact: Matthew Brenner, M.D    714-456-5150    mbrenner@uci.edu   
Contact: Sari Mahon, PhD    (949) 824-3924    mahonsb@uci.edu   
Principal Investigator: Matthew Brenner, M.D.         
Sub-Investigator: Thomas Ahlering, PhD         
Sub-Investigator: Douglas Skarecky, M         
Sub-Investigator: David Mukai, BS         
Urology department, UCI Medical Center Recruiting
Orange, California, United States, 92868
Contact: Matthew Brenner, M.D         
Contact: Sari B Mahon    (949) 824-3924    mahonsb@uci.edu   
Principal Investigator: Matthew Brenner, M.D         
Sub-Investigator: Thomas Ahlering, M.D         
Sponsors and Collaborators
University of California, Irvine
Beckman Laser Institute University of California Irvine
Investigators
Principal Investigator: Matthew Brenner, M.D Beckman Laser Institute
  More Information

Responsible Party: Beckman Laser Institute and Medical Center, Matthew Brenner, M.D.,Department of Pulmonary and Critical Care Medicine, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00581503     History of Changes
Other Study ID Numbers: NIH/LAMMP-2006-4981
First Submitted: December 19, 2007
First Posted: December 27, 2007
Last Update Posted: February 10, 2017
Last Verified: February 2017

Keywords provided by Beckman Laser Institute and Medical Center, University of California, Irvine:
early detection of lung and pleural cancer
early detection of prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases